Send to:

Choose Destination
See comment in PubMed Commons below
BMC Med. 2010 Nov 29;8:77. doi: 10.1186/1741-7015-8-77.

Advances in drug therapy for systemic lupus erythematosus.

Author information

  • 1Division of Rheumatology, Cedars-Sinai Medical Center, 8737 Beverly Blvd, Suite 302, West Hollywood, CA 90048, USA.


Systemic lupus erythematosus (SLE) is an autoimmune disorder that afflicts 500,000 people in the United States. There has not been a new SLE drug approved in the United States since 1958. However, a guidance document issued by the Food and Drug Administration in 2005 provided a roadmap for investigators which spawned numerous ongoing clinical trials. Among these, Belimumab, a monoclonal antibody to soluble B lymphocyte stimulator, met its primary endpoints in two large trials and will probably obtain FDA approval soon. Other promising agents targeting a variety of mechanisms of action are currently in development. This minireview highlights the latest therapies under investigation in SLE and gives an overview of the pathways that are specifically being targeted.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Write to the Help Desk